Abiopharma

News list

SAB Biotherapeutics (SABS)

Event
June 07, 2022, 12:00 UTC

(99% Neutral) SAB BIOTHERAPEUTICS, INC. (SABS) Announces Enrollment Update for used Due to Pandemic-Related Challenges, Patient Enrollment Issues, Manufacturing Considerations, Efficacy Assessment

Full text

News bot Oct. 2, 2025, 4:41 a.m.

📋 SAB BIOTHERAPEUTICS, INC. (SABS) - Clinical Trial Update

Filing Date: 2022-06-07

Accepted: 2022-06-07 08:00:52

Event Type: Clinical Trial Update

Event Details:

SAB Biotherapeutics (SABS) Announces Clinical Trial Update SAB Biotherapeutics (SABS) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: used, given
Diseases/Conditions: relation to holding
Collaboration: SAB Biotherapeutics, Inc.

🔬 Clinical Development Pipeline (SAB BIOTHERAPEUTICS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Dose Level 4, VNX-202	GENETIC	Phase PHASE1	HER2 Expressing Solid Tumors	ClinicalTrials.gov
Dose Level 3, VNX-202	GENETIC	Phase PHASE1	HER2 Expressing Solid Tumors	ClinicalTrials.gov
Dose Level 2, VNX-202	GENETIC	Phase PHASE1	HER2 Expressing Solid Tumors	ClinicalTrials.gov
Dose Level 1, VNX-202	GENETIC	Phase PHASE1	HER2 Expressing Solid Tumors	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval: Not available
Executive Changes: Not available

Structured Data:

Company Name: SAB Biotherapeutics
CIK: 0001833214
Ticker Symbol: SABS
Period End Date: 2022-06-07
Document Type: 8-K